A Ticker Is Not a Business: Reading the Market's Long TailGlobal Report·Oct 20, 2026 at 10:51 AMFIS-1.98%ROST-3.11%
ECARX Closes Flyme Deal as the Long Bond Pushes Past 5.3%Global Report·Oct 13, 2026 at 10:50 AMECX0.00%REA-2.22%
Beyond the Divestiture: How Specialization Defines 2026's Biopharma WinnersGlobal Report·Oct 13, 2026 at 10:15 AMPMEC-1.48%PHIO-2.30%
Sector Reshuffle: AI Bets and Boardroom Revolutions Drive Corporate TurnaroundsGlobal Report·Oct 13, 2026 at 09:23 AMCTSH-4.31%ECX0.00%
Alpha Buying: 4 Biotech Stocks Insiders Are Betting Onbenzinga_article·Oct 8, 2026 at 03:32 PMMAIA+1.77%NTHI+10.85%
Nobody Covers These Ten US Stocks. So Who Sets the Price?Global Report·Oct 6, 2026 at 10:49 AMQ+0.97%KOPN+0.90%
Deal Turbulence and Policy Windfalls: Micro-Caps Rewrite the RulesGlobal Report·Oct 6, 2026 at 09:16 AMDQ+1.19%DPRO-0.56%
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XENE Stock NewsStockTitan·Oct 2, 2026 at 12:01 PMXENE-3.18%
Xenon Pharma CEO Ian Mortimer acquires $1,121,400 in common sharesPUBT·Oct 1, 2026 at 01:20 PMXENE-3.18%
Is Xenon Pharmaceuticals (XENE) Undervalued On Its FDA Filing And Psychiatry Trial Pause?Simplywall·Sep 29, 2026 at 06:11 PMXENE-3.18%
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability ReviewMarket Beat·Sep 27, 2026 at 04:02 PMXENE-3.18%
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)prnewswire·Sep 22, 2026 at 10:18 PMXENE-3.18%
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | XENE Stock NewsStockTitan·Sep 21, 2026 at 12:01 PMXENE-3.18%
